Our Reports
Automotive Reports Electronics & Semiconductor Telecom & IT Technology & IT Consumer Goods Healthcare Food & Beverages Chemical
Our Links
About Us Contact Us Press Release News Our Blogs

Int'l : +1(646) 600-5072 | query@kbvresearch.com

Global Telmisartan Market By Indication (Hypertension and Cardiovascular Risk Reduction), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies), By Regional Outlook, Industry Analysis Report and Forecast, 2020 - 2026

Published Date : 21-Apr-2021

Pages: 149

Formats: PDF

COVID-19 Impact on the Telmisartan Market

The Global Telmisartan Market size is expected to reach $4 billion by 2026, rising at a market growth of 5.8% CAGR during the forecast period. Telmisartan refers to an angiotensin receptor blocker (ARB) utilized alone or combined with other agents in order to treat stroke management, cardiac arrest, and hypertension. Telmisartan is available in various generic forms and under the trade name Micardis. Telmisartan also has its side effects including cough, dizziness, sinus pain, lightheadedness, and others.

Aspects such as rising cases of high blood pressure, growing occurrences of chronic diseases like diabetes, the increasing geriatric population would boost the growth of the global telmisartan market. Moreover, a growing number of approval for abbreviated new drug applications (ANDA) for the production of generic telmisartan tablets would present new growth avenues for the global telmisartan market.

Some of the factors that are responsible for the growth of the Telmisartan market including rising cases of high blood pressure (hypertension), increasing geriatric population, and a surge in supportive government initiatives for increasing awareness about blood pressure diseases. Moreover, the telmisartan market would be supplemented by various factors such as increasing marketing approvals for generic forms of telmisartan, rising sedentary lifestyle, and rising occurrences of chronic diseases like kidney and diabetes.

The World Health Organization (WHO) on January 30, 2020, announced COVID-19 a global public health emergency. COVID-19 has severely impacted approximately 210 nations around the world. Telmisartan tablets manufacturing and distributing companies have been severely impacted by COVID-19 to a certain extent, due to the closure in several COVID-19 affected nations and a surge in the number of healthcare workers falling ill during the outbreak of the COVID-19 pandemic, resulting in the storage of supply.

Indication Outlook

Based on Indication, the market is segmented into Hypertension and Cardiovascular Risk Reduction. Currently, the hypertension segment procured the maximum revenue share of the market in 2019 and would maintain a similar trend during the forecast period. Various determinants including rising hypertension cases, surging demand for antihypertensive drugs, and increasing awareness about hypertension & its management by holding campaigns on a worldwide level would propel the growth of the segment.

Distribution Channel Outlook

Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. On the basis of distribution channels, the market is segregated into drug stores & retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies segment would obtain a prominent revenue share during the forecast period owing to the increasing number of hospital pharmacies around the globe and broad-scale accessibility of hospital pharmacies. Moreover, the growth of the segment can be credited to the growing hospitalized hypertension patients & development in the structure of hospital pharmacies in developing countries like China and India.

Telmisartan Market Report Coverage
Report Attribute Details
Market size value in 2019 USD 2.9 Billion
Market size forecast in 2026 USD 4 Billion
Base Year 2019
Historical Period 2016 to 2018
Forecast Period 2020 to 2026
Revenue Growth Rate CAGR of 5.8% from 2020 to 2026
Number of Pages 149
Number of Tables 250
Report coverage Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling
Segments covered Indication, Distribution Channel, Region
Country scope US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria
Growth Drivers
  • The increasing number of lifestyle diseases to support the consumption
  • Increasing cases of chronic diseases around the world
Restraints
  • Telmisartan may combine with other drugs and has some side effects

Free Valuable Insights: Global Telmisartan Market to reach a market size of $4 Billion by 2026

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America would emerge as the leading region of the global telmisartan market. It is owing to the various product launches in the U.S. For example, in July 2014, Mylan Inc., an international pharmaceutical company introduced telmisartan tablets USP, 20mg, 40mg, and 80 mg, which are the generic form of Boehringer Ingelheim’s Micardis tablets that got the final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA).

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC (GSK), Mylan N.V., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Cadila Healthcare Ltd. (Zydus Cadila).

Recent Strategies Deployed in Telmisartan Market

  • Jun-2020: Cipla partnered with Boehringer Ingelheim India. Under this partnership, the companies aimed to co-market three new oral anti-diabetics drugs Oboravo (Empagliflozin), Oboravo Met (Empagliflozin+Metformin), and Tiptengio (Empagliflozin+Linagliptin). Empagliflozin is approved for glucose-control in patients with type-2 diabetes; it is also approved to decrease the risk of cardiovascular death, in patients with type-2 diabetes and cardiovascular disease.
  • Feb-2019: Cipla came into partnership with Wellthy Therapeutics Private Limited. The partnership aimed to provide a combination of pharmacotherapy and digital therapeutics for enhanced patient outcomes in the chronic therapies of diabetology and cardiology.
  • Feb-2019: Teva Pharmaceutical introduced ALYQ, a generic version of ADCIRCA1 (tadalafil) tablets, 20 mg in the U.S. It is a phosphodiesterase 5 (PDE5) inhibitor suggested for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to enhance exercise ability.
  • Oct-2018: Boehringer Ingelheim received the approval of SEMINTRA 10 mg/mL oral solution by the U.S. Food & Drug Administration. SEMINTRA solution is used to control systemic hypertension in cats, a common condition in older cats. It is developed to make the management of feline hypertension easier for cat owners and veterinarians. SEMINTRA is the only FDA-approved solution for feline hypertension in an easy-to-give formulation.
  • Oct-2018: Cipla got approval from the US health regulator to market Metoprolol tablets. These tablets are utilized to cure hypertension and various cardiac conditions. Metoprolol succinate extended-release tablets are used to treat hypertension, lower, Angina Pectoris.
  • Sep-2018: Sun Pharmaceutical Industries Ltd. received approval from the U.S. Food and Drug Administration (USFDA) for its New Drug Application (NDA) of XELPROSTM 0.005%. It helps in reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The received approval is from Sun Pharma’s Halol facility.
  • Aug-2018: Mylan N.V. launched Tadalafil Tablets USP, 20 mg in the U.S. It was the first generic version of the reference listed drug, Eli Lilly and Company's Adcirca. Mylan Pharmaceuticals got approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA). It also got 180 days of marketing exclusivity for this product that is used for the treatment of pulmonary arterial hypertension to enhance exercise ability.
  • Aug-2018: Sun Pharmaceutical released Kapspargo Sprinkle extended-release capsules in the US. It helps in treating hypertension (to lower blood pressure), angina pectoris (chest pain), and heart failure (to minimize the risk of cardiovascular mortality and heart failure hospitalization in patients with heart failure).
  • Oct-2017: Boehringer Ingelheim extended its agreement with Astellas Pharma, a Japanese multinational pharmaceutical company. The extended agreement focused on the sales of telmisartan (Micardis family) in Japan.
  • Aug-2017: Zydus Cadila received approval from the USFDA to market Telmisartan and Hydrochlorothiazide Tablets USP, in the dosage of 40 mg/12.5 mg, 80mg/12.5 mg, and 80mg/25 mg. Telmisartan and Hydrochlorothiazide Tablets are utilized to cure hypertension.
  • May-2017: Aurobindo Pharma got approval from the US Food and Drug Administration (FDA) for its generic version of olmesartan medoxomil and hydrochlorothiazide tablets in 20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg doses. These tablets are used for treating hypertension to lower blood pressure.
  • Jan-2017: Agile Pharma, a subsidiary of Aurobindo Pharma completed its acquisition of Generis Farmacêutica, from Magnum Capital Partners. The acquisition strengthened the position of Aurobindo group in the pharmaceutical market in Portugal, with 271 products in its portfolio.
  • Nov-2016: Teva Pharmaceutical got the approval of generic Tribenzor 1 tablets in the U.S from FDA. Teva also got approval and launched generic Azor2 tablets in the U.S. These tablets improve Teva’s antihypertensive portfolio.

Scope of the Study

Market Segments Covered in the Report:

By Indication

  • Hypertension
  • Cardiovascular Risk Reduction

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • Abbott Laboratories
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • GlaxoSmithKline PLC (GSK)
  • Mylan N.V.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Cadila Healthcare Ltd. (Zydus Cadila)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Telmisartan Market, by Indication
1.4.2 Global Telmisartan Market, by Distribution Channel
1.4.3 Global Telmisartan Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Global Telmisartan Market by Indication
3.1 Global Hypertension Market by Region
3.2 Global Cardiovascular Risk Reduction Market by Region

Chapter 4. Global Telmisartan Market by Distribution Channel
4.1 Global Hospital Pharmacies Market by Region
4.2 Global Drug Stores and Retail Pharmacies Market by Region
4.3 Global Online Pharmacies Market by Region

Chapter 5. Global Telmisartan Market by Region
5.1 North America Telmisartan Market
5.1.1 North America Telmisartan Market by Indication
5.1.1.1 North America Hypertension Market by Country
5.1.1.2 North America Cardiovascular Risk Reduction Market by Country
5.1.2 North America Telmisartan Market by Distribution Channel
5.1.2.1 North America Hospital Pharmacies Market by Country
5.1.2.2 North America Drug Stores and Retail Pharmacies Market by Country
5.1.2.3 North America Online Pharmacies Market by Country
5.1.3 North America Telmisartan Market by Country
5.1.3.1 US Telmisartan Market
5.1.3.1.1 US Telmisartan Market by Indication
5.1.3.1.2 US Telmisartan Market by Distribution Channel
5.1.3.2 Canada Telmisartan Market
5.1.3.2.1 Canada Telmisartan Market by Indication
5.1.3.2.2 Canada Telmisartan Market by Distribution Channel
5.1.3.3 Mexico Telmisartan Market
5.1.3.3.1 Mexico Telmisartan Market by Indication
5.1.3.3.2 Mexico Telmisartan Market by Distribution Channel
5.1.3.4 Rest of North America Telmisartan Market
5.1.3.4.1 Rest of North America Telmisartan Market by Indication
5.1.3.4.2 Rest of North America Telmisartan Market by Distribution Channel
5.2 Europe Telmisartan Market
5.2.1 Europe Telmisartan Market by Indication
5.2.1.1 Europe Hypertension Market by Country
5.2.1.2 Europe Cardiovascular Risk Reduction Market by Country
5.2.2 Europe Telmisartan Market by Distribution Channel
5.2.2.1 Europe Hospital Pharmacies Market by Country
5.2.2.2 Europe Drug Stores and Retail Pharmacies Market by Country
5.2.2.3 Europe Online Pharmacies Market by Country
5.2.3 Europe Telmisartan Market by Country
5.2.3.1 Germany Telmisartan Market
5.2.3.1.1 Germany Telmisartan Market by Indication
5.2.3.1.2 Germany Telmisartan Market by Distribution Channel
5.2.3.2 UK Telmisartan Market
5.2.3.2.1 UK Telmisartan Market by Indication
5.2.3.2.2 UK Telmisartan Market by Distribution Channel
5.2.3.3 France Telmisartan Market
5.2.3.3.1 France Telmisartan Market by Indication
5.2.3.3.2 France Telmisartan Market by Distribution Channel
5.2.3.4 Russia Telmisartan Market
5.2.3.4.1 Russia Telmisartan Market by Indication
5.2.3.4.2 Russia Telmisartan Market by Distribution Channel
5.2.3.5 Spain Telmisartan Market
5.2.3.5.1 Spain Telmisartan Market by Indication
5.2.3.5.2 Spain Telmisartan Market by Distribution Channel
5.2.3.6 Italy Telmisartan Market
5.2.3.6.1 Italy Telmisartan Market by Indication
5.2.3.6.2 Italy Telmisartan Market by Distribution Channel
5.2.3.7 Rest of Europe Telmisartan Market
5.2.3.7.1 Rest of Europe Telmisartan Market by Indication
5.2.3.7.2 Rest of Europe Telmisartan Market by Distribution Channel
5.3 Asia Pacific Telmisartan Market
5.3.1 Asia Pacific Telmisartan Market by Indication
5.3.1.1 Asia Pacific Hypertension Market by Country
5.3.1.2 Asia Pacific Cardiovascular Risk Reduction Market by Country
5.3.2 Asia Pacific Telmisartan Market by Distribution Channel
5.3.2.1 Asia Pacific Hospital Pharmacies Market by Country
5.3.2.2 Asia Pacific Drug Stores and Retail Pharmacies Market by Country
5.3.2.3 Asia Pacific Online Pharmacies Market by Country
5.3.3 Asia Pacific Telmisartan Market by Country
5.3.3.1 China Telmisartan Market
5.3.3.1.1 China Telmisartan Market by Indication
5.3.3.1.2 China Telmisartan Market by Distribution Channel
5.3.3.2 India Telmisartan Market
5.3.3.2.1 India Telmisartan Market by Indication
5.3.3.2.2 India Telmisartan Market by Distribution Channel
5.3.3.3 Japan Telmisartan Market
5.3.3.3.1 Japan Telmisartan Market by Indication
5.3.3.3.2 Japan Telmisartan Market by Distribution Channel
5.3.3.4 South Korea Telmisartan Market
5.3.3.4.1 South Korea Telmisartan Market by Indication
5.3.3.4.2 South Korea Telmisartan Market by Distribution Channel
5.3.3.5 Malaysia Telmisartan Market
5.3.3.5.1 Malaysia Telmisartan Market by Indication
5.3.3.5.2 Malaysia Telmisartan Market by Distribution Channel
5.3.3.6 Malaysia Telmisartan Market
5.3.3.6.1 Malaysia Telmisartan Market by Indication
5.3.3.6.2 Malaysia Telmisartan Market by Distribution Channel
5.3.3.7 Rest of Asia Pacific Telmisartan Market
5.3.3.7.1 Rest of Asia Pacific Telmisartan Market by Indication
5.3.3.7.2 Rest of Asia Pacific Telmisartan Market by Distribution Channel
5.4 LAMEA Telmisartan Market
5.4.1 LAMEA Telmisartan Market by Indication
5.4.1.1 LAMEA Hypertension Market by Country
5.4.1.2 LAMEA Cardiovascular Risk Reduction Market by Country
5.4.2 LAMEA Telmisartan Market by Distribution Channel
5.4.2.1 LAMEA Hospital Pharmacies Market by Country
5.4.2.2 LAMEA Drug Stores and Retail Pharmacies Market by Country
5.4.2.3 LAMEA Online Pharmacies Market by Country
5.4.3 LAMEA Telmisartan Market by Country
5.4.3.1 Brazil Telmisartan Market
5.4.3.1.1 Brazil Telmisartan Market by Indication
5.4.3.1.2 Brazil Telmisartan Market by Distribution Channel
5.4.3.2 Argentina Telmisartan Market
5.4.3.2.1 Argentina Telmisartan Market by Indication
5.4.3.2.2 Argentina Telmisartan Market by Distribution Channel
5.4.3.3 UAE Telmisartan Market
5.4.3.3.1 UAE Telmisartan Market by Indication
5.4.3.3.2 UAE Telmisartan Market by Distribution Channel
5.4.3.4 Saudi Arabia Telmisartan Market
5.4.3.4.1 Saudi Arabia Telmisartan Market by Indication
5.4.3.4.2 Saudi Arabia Telmisartan Market by Distribution Channel
5.4.3.5 South Africa Telmisartan Market
5.4.3.5.1 South Africa Telmisartan Market by Indication
5.4.3.5.2 South Africa Telmisartan Market by Distribution Channel
5.4.3.6 Nigeria Telmisartan Market
5.4.3.6.1 Nigeria Telmisartan Market by Indication
5.4.3.6.2 Nigeria Telmisartan Market by Distribution Channel
5.4.3.7 Rest of LAMEA Telmisartan Market
5.4.3.7.1 Rest of LAMEA Telmisartan Market by Indication
5.4.3.7.2 Rest of LAMEA Telmisartan Market by Distribution Channel

Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Aurobindo Pharma Limited
6.2.1 Company Overview
6.2.1 Financial Analysis
6.2.2 Regional Analysis
6.2.3 Research & Development Expense
6.2.4 Recent strategies and developments:
6.2.4.1 Approvals:
6.2.4.2 Acquisition and Mergers:
6.3 Boehringer Ingelheim International GmbH
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Approvals:
6.3.5.2 Partnerships, Collaborations, and Agreements:
6.4 Cipla Limited
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Approvals:
6.5 GlaxoSmithKline PLC (GSK)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Mylan N.V.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Product Launches and Product Expansions:
6.7 Sanofi S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.8 Sun Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Approvals:
6.8.5.2 Product Launches and Product Expansions:
6.9 Teva Pharmaceutical Industries Ltd.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expenses
6.9.5 Recent strategies and developments:
6.9.5.1 Approvals:
6.9.5.2 Product Launches and Product Expansions:
6.10. Cadila Healthcare Ltd. (Zydus Cadila)
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
6.10.5 Recent strategies and developments:
6.10.5.1 Approvals:
TABLE 1 Global Telmisartan Market, 2016 - 2019, USD Million
TABLE 2 Global Telmisartan Market, 2020 - 2026, USD Million
TABLE 3 Global Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 4 Global Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 5 Global Hypertension Market by Region, 2016 - 2019, USD Million
TABLE 6 Global Hypertension Market by Region, 2020 - 2026, USD Million
TABLE 7 Global Cardiovascular Risk Reduction Market by Region, 2016 - 2019, USD Million
TABLE 8 Global Cardiovascular Risk Reduction Market by Region, 2020 - 2026, USD Million
TABLE 9 Global Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 10 Global Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 11 Global Hospital Pharmacies Market by Region, 2016 - 2019, USD Million
TABLE 12 Global Hospital Pharmacies Market by Region, 2020 - 2026, USD Million
TABLE 13 Global Drug Stores and Retail Pharmacies Market by Region, 2016 - 2019, USD Million
TABLE 14 Global Drug Stores and Retail Pharmacies Market by Region, 2020 - 2026, USD Million
TABLE 15 Global Online Pharmacies Market by Region, 2016 - 2019, USD Million
TABLE 16 Global Online Pharmacies Market by Region, 2020 - 2026, USD Million
TABLE 17 Global Telmisartan Market by Region, 2016 - 2019, USD Million
TABLE 18 Global Telmisartan Market by Region, 2020 - 2026, USD Million
TABLE 19 North America Telmisartan Market, 2016 - 2019, USD Million
TABLE 20 North America Telmisartan Market, 2020 - 2026, USD Million
TABLE 21 North America Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 22 North America Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 23 North America Hypertension Market by Country, 2016 - 2019, USD Million
TABLE 24 North America Hypertension Market by Country, 2020 - 2026, USD Million
TABLE 25 North America Cardiovascular Risk Reduction Market by Country, 2016 - 2019, USD Million
TABLE 26 North America Cardiovascular Risk Reduction Market by Country, 2020 - 2026, USD Million
TABLE 27 North America Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 28 North America Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 29 North America Hospital Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 30 North America Hospital Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 31 North America Drug Stores and Retail Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 32 North America Drug Stores and Retail Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 33 North America Online Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 34 North America Online Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 35 North America Telmisartan Market by Country, 2016 - 2019, USD Million
TABLE 36 North America Telmisartan Market by Country, 2020 - 2026, USD Million
TABLE 37 US Telmisartan Market, 2016 - 2019, USD Million
TABLE 38 US Telmisartan Market, 2020 - 2026, USD Million
TABLE 39 US Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 40 US Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 41 US Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 42 US Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 43 Canada Telmisartan Market, 2016 - 2019, USD Million
TABLE 44 Canada Telmisartan Market, 2020 - 2026, USD Million
TABLE 45 Canada Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 46 Canada Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 47 Canada Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 48 Canada Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 49 Mexico Telmisartan Market, 2016 - 2019, USD Million
TABLE 50 Mexico Telmisartan Market, 2020 - 2026, USD Million
TABLE 51 Mexico Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 52 Mexico Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 53 Mexico Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 54 Mexico Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 55 Rest of North America Telmisartan Market, 2016 - 2019, USD Million
TABLE 56 Rest of North America Telmisartan Market, 2020 - 2026, USD Million
TABLE 57 Rest of North America Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 58 Rest of North America Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 59 Rest of North America Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 60 Rest of North America Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 61 Europe Telmisartan Market, 2016 - 2019, USD Million
TABLE 62 Europe Telmisartan Market, 2020 - 2026, USD Million
TABLE 63 Europe Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 64 Europe Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 65 Europe Hypertension Market by Country, 2016 - 2019, USD Million
TABLE 66 Europe Hypertension Market by Country, 2020 - 2026, USD Million
TABLE 67 Europe Cardiovascular Risk Reduction Market by Country, 2016 - 2019, USD Million
TABLE 68 Europe Cardiovascular Risk Reduction Market by Country, 2020 - 2026, USD Million
TABLE 69 Europe Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 70 Europe Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 71 Europe Hospital Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 72 Europe Hospital Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 73 Europe Drug Stores and Retail Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 74 Europe Drug Stores and Retail Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 75 Europe Online Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 76 Europe Online Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 77 Europe Telmisartan Market by Country, 2016 - 2019, USD Million
TABLE 78 Europe Telmisartan Market by Country, 2020 - 2026, USD Million
TABLE 79 Germany Telmisartan Market, 2016 - 2019, USD Million
TABLE 80 Germany Telmisartan Market, 2020 - 2026, USD Million
TABLE 81 Germany Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 82 Germany Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 83 Germany Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 84 Germany Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 85 UK Telmisartan Market, 2016 - 2019, USD Million
TABLE 86 UK Telmisartan Market, 2020 - 2026, USD Million
TABLE 87 UK Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 88 UK Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 89 UK Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 90 UK Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 91 France Telmisartan Market, 2016 - 2019, USD Million
TABLE 92 France Telmisartan Market, 2020 - 2026, USD Million
TABLE 93 France Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 94 France Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 95 France Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 96 France Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 97 Russia Telmisartan Market, 2016 - 2019, USD Million
TABLE 98 Russia Telmisartan Market, 2020 - 2026, USD Million
TABLE 99 Russia Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 100 Russia Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 101 Russia Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 102 Russia Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 103 Spain Telmisartan Market, 2016 - 2019, USD Million
TABLE 104 Spain Telmisartan Market, 2020 - 2026, USD Million
TABLE 105 Spain Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 106 Spain Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 107 Spain Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 108 Spain Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 109 Italy Telmisartan Market, 2016 - 2019, USD Million
TABLE 110 Italy Telmisartan Market, 2020 - 2026, USD Million
TABLE 111 Italy Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 112 Italy Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 113 Italy Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 114 Italy Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 115 Rest of Europe Telmisartan Market, 2016 - 2019, USD Million
TABLE 116 Rest of Europe Telmisartan Market, 2020 - 2026, USD Million
TABLE 117 Rest of Europe Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 118 Rest of Europe Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 119 Rest of Europe Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 120 Rest of Europe Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 121 Asia Pacific Telmisartan Market, 2016 - 2019, USD Million
TABLE 122 Asia Pacific Telmisartan Market, 2020 - 2026, USD Million
TABLE 123 Asia Pacific Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 124 Asia Pacific Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 125 Asia Pacific Hypertension Market by Country, 2016 - 2019, USD Million
TABLE 126 Asia Pacific Hypertension Market by Country, 2020 - 2026, USD Million
TABLE 127 Asia Pacific Cardiovascular Risk Reduction Market by Country, 2016 - 2019, USD Million
TABLE 128 Asia Pacific Cardiovascular Risk Reduction Market by Country, 2020 - 2026, USD Million
TABLE 129 Asia Pacific Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 130 Asia Pacific Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 131 Asia Pacific Hospital Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 132 Asia Pacific Hospital Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 133 Asia Pacific Drug Stores and Retail Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 134 Asia Pacific Drug Stores and Retail Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 135 Asia Pacific Online Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 136 Asia Pacific Online Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 137 Asia Pacific Telmisartan Market by Country, 2016 - 2019, USD Million
TABLE 138 Asia Pacific Telmisartan Market by Country, 2020 - 2026, USD Million
TABLE 139 China Telmisartan Market, 2016 - 2019, USD Million
TABLE 140 China Telmisartan Market, 2020 - 2026, USD Million
TABLE 141 China Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 142 China Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 143 China Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 144 China Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 145 India Telmisartan Market, 2016 - 2019, USD Million
TABLE 146 India Telmisartan Market, 2020 - 2026, USD Million
TABLE 147 India Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 148 India Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 149 India Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 150 India Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 151 Japan Telmisartan Market, 2016 - 2019, USD Million
TABLE 152 Japan Telmisartan Market, 2020 - 2026, USD Million
TABLE 153 Japan Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 154 Japan Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 155 Japan Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 156 Japan Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 157 South Korea Telmisartan Market, 2016 - 2019, USD Million
TABLE 158 South Korea Telmisartan Market, 2020 - 2026, USD Million
TABLE 159 South Korea Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 160 South Korea Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 161 South Korea Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 162 South Korea Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 163 Malaysia Telmisartan Market, 2016 - 2019, USD Million
TABLE 164 Malaysia Telmisartan Market, 2020 - 2026, USD Million
TABLE 165 Malaysia Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 166 Malaysia Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 167 Malaysia Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 168 Malaysia Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 169 Malaysia Telmisartan Market, 2016 - 2019, USD Million
TABLE 170 Malaysia Telmisartan Market, 2020 - 2026, USD Million
TABLE 171 Malaysia Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 172 Malaysia Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 173 Malaysia Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 174 Malaysia Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 175 Rest of Asia Pacific Telmisartan Market, 2016 - 2019, USD Million
TABLE 176 Rest of Asia Pacific Telmisartan Market, 2020 - 2026, USD Million
TABLE 177 Rest of Asia Pacific Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 178 Rest of Asia Pacific Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 179 Rest of Asia Pacific Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 180 Rest of Asia Pacific Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 181 LAMEA Telmisartan Market, 2016 - 2019, USD Million
TABLE 182 LAMEA Telmisartan Market, 2020 - 2026, USD Million
TABLE 183 LAMEA Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 184 LAMEA Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 185 LAMEA Hypertension Market by Country, 2016 - 2019, USD Million
TABLE 186 LAMEA Hypertension Market by Country, 2020 - 2026, USD Million
TABLE 187 LAMEA Cardiovascular Risk Reduction Market by Country, 2016 - 2019, USD Million
TABLE 188 LAMEA Cardiovascular Risk Reduction Market by Country, 2020 - 2026, USD Million
TABLE 189 LAMEA Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 190 LAMEA Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 191 LAMEA Hospital Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 192 LAMEA Hospital Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 193 LAMEA Drug Stores and Retail Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 194 LAMEA Drug Stores and Retail Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 195 LAMEA Online Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 196 LAMEA Online Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 197 LAMEA Telmisartan Market by Country, 2016 - 2019, USD Million
TABLE 198 LAMEA Telmisartan Market by Country, 2020 - 2026, USD Million
TABLE 199 Brazil Telmisartan Market, 2016 - 2019, USD Million
TABLE 200 Brazil Telmisartan Market, 2020 - 2026, USD Million
TABLE 201 Brazil Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 202 Brazil Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 203 Brazil Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 204 Brazil Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 205 Argentina Telmisartan Market, 2016 - 2019, USD Million
TABLE 206 Argentina Telmisartan Market, 2020 - 2026, USD Million
TABLE 207 Argentina Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 208 Argentina Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 209 Argentina Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 210 Argentina Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 211 UAE Telmisartan Market, 2016 - 2019, USD Million
TABLE 212 UAE Telmisartan Market, 2020 - 2026, USD Million
TABLE 213 UAE Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 214 UAE Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 215 UAE Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 216 UAE Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 217 Saudi Arabia Telmisartan Market, 2016 - 2019, USD Million
TABLE 218 Saudi Arabia Telmisartan Market, 2020 - 2026, USD Million
TABLE 219 Saudi Arabia Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 220 Saudi Arabia Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 221 Saudi Arabia Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 222 Saudi Arabia Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 223 South Africa Telmisartan Market, 2016 - 2019, USD Million
TABLE 224 South Africa Telmisartan Market, 2020 - 2026, USD Million
TABLE 225 South Africa Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 226 South Africa Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 227 South Africa Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 228 South Africa Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 229 Nigeria Telmisartan Market, 2016 - 2019, USD Million
TABLE 230 Nigeria Telmisartan Market, 2020 - 2026, USD Million
TABLE 231 Nigeria Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 232 Nigeria Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 233 Nigeria Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 234 Nigeria Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 235 Rest of LAMEA Telmisartan Market, 2016 - 2019, USD Million
TABLE 236 Rest of LAMEA Telmisartan Market, 2020 - 2026, USD Million
TABLE 237 Rest of LAMEA Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 238 Rest of LAMEA Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 239 Rest of LAMEA Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 240 Rest of LAMEA Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 241 Key Information – Abbott Laboratories
TABLE 242 key information – Aurobindo Pharma Limited
TABLE 243 Key Information – Boehringer Ingelheim International GmbH
TABLE 244 Key Information – Cipla Limited
TABLE 245 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 246 Key Information – Mylan N.V.
TABLE 247 Key Information – Sanofi S.A.
TABLE 248 Key Information – Sun Pharmaceutical Industries Ltd.
TABLE 249 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 250 Key Information – Cadila Healthcare Ltd.

List of Figures
FIG 1 Methodology for the research

Purchase Full Report of
Telmisartan Market

Buy Now

Avail up to 60% discount on subscription plans on

SUBSCRIPTION MODEL

© 2024 KBV Research. All Rights Reserved